Neuros Medical receives $1.5M Applied Research and Technology Development Award from DMRDP

Neuros Medical, Inc., a medical device company announced today they have received notification of award for $1.5 million from the U.S. Department of Defense. The Applied Research and Technology Development Award was provided by the Defense Medical Research and Development Program (DMRDP). The funding will aid technology development and human clinical research for their novel neurostimulation therapy, called Nerve Block, focusing on the treatment of chronic residual limb pain which is suffered by nearly one million amputees. The Company's technology utilizes high frequency alternating current stimulation to block chronic pain signals in the peripheral nervous system.

“Our efforts via this funding will greatly advance our technology's application in providing a proven treatment for patients with chronic pain, specifically residual limb pain.”

"The U.S. Military holds a strong commitment to continued care for the wounded warrior, even after the battlefield experience," stated Jon J. Snyder, President and CEO of Neuros Medical. "Our efforts via this funding will greatly advance our technology's application in providing a proven treatment for patients with chronic pain, specifically residual limb pain." In addition, military casualties and amputations experienced by those serving in Iraq and Afghanistan have contributed to the need to develop effective treatments for patients suffering from chronic residual limb pain.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Disrupted glucose transport in oligodendrocytes linked to myelin thinning and aging in new research